Journal of obstetrics and women's diseasesJournal of obstetrics and women's diseases1684-04611683-9366Eco-Vector691810.17816/JOWD66446-50Research ArticleThe problem of "thin" endometrium in reproductive medicine: experience of application of recombinant Interleukin-2 to prepare patients to assisted reproductive technologies programsLysenkoOlga V.<p>doctor of medical sciences, docent, professor of department of obstetrics and Gynecology</p>lysenko_o_v@mail.ruRozhdzestvenskayaTatyana A.<p>candidate of medical sciences, senior lecturer of department of obstetrics and Gynecology</p>lysenko_o_v@mail.ruVitebsk State Medical UniversityFamily Health Center BINA15072017664465015072017Copyright © 2017, Lysenko O.V., Rozhdzestvenskaya T.A.2017<p><strong>Introduction</strong>. Thin endometrium is known affect negatively to reproductive function. Treatment of thin endometrium remains a problem and subject of future major studies.</p>
<p><strong>Aim</strong>. To justify the possibility of applying of recombinant interleikina-2 person late reproductive age patients with thin endometrium before using assisted reproductive technologies.</p>
<p><strong>Matherials and Methods</strong>. We examined a total of 64 late reproductive age women. Three groups of patients were analyzed. The first investigated group included 25 women with histologically proven chronic endometritis; the comparison group included 20 patients with endometrium of the early proliferative phase; the second investigated group included 19 patients with thin endometrium, with indications for the conduct of in vitro fertilization. Interleukin 2, interleukin-4, tumor necrosis factor alpha, interleukin-1, Interleukin-6, interleukin-8, interleukin-10, IFN- concentrations were determined by enzyme linked immunosorbent assay in serum and aspirates from the uterine cavity in first investigated group and comparison group. Vaginal ultrasonic examination was made for women of second investigated group in first and second phase of menstrual cycle before and after recombinant human interlejkinom-2 treatment. Statistical data processing was performed using application software package Statistica 6.0 (StatSoft, Ink. 19942001), adapted for biomedical research. P 0.05 was considered significant.</p>
<p><strong>Results</strong>. Were found that concentrations of interleukin 2, interleukin-10 significantly reduced and concentrations of tumor necrosis factor alpha, interleukin-1, Interleukin-6 and interleukin-8 significantly increased in aspirates from the uterine cavity in women of late reproductive age with chronic endometritis. All changes occur at the local level in chronic endometritis. Endometrial thickness a statistically significant increase after use of recombinant human interlejkinom-2 in patients with infertility and chronic endometritis.</p>
<p><strong>Conclusions</strong>. Application of recombinant interleukin-2 in patients with thin endometrium can become optimal schema therapy, which requires further study.</p>thin endometriumtreatmentхронический эндометриттонкий эндометрийлечениехронический эндометриттонкий эндометрийлечениесhronic endometritis[1. Зароченцева Н.В., Аршакян А.К., Меньшикова Н.С., Титченко Ю.П. Хронический эндометрит: этиология, клиника, диагностика, лечение // Российский вестник акушера-гинеколога. – 2013. – Т. 13. – № 5. – С. 21–27. [Zarochentseva NV, Arshakyan AK, Menshikova NS, Titchenko YuP. Chronic endometritis: etiology, clinical presentation, diagnosis, treatment. Rossiyskiy vestnik akushera-ginekologa. 2013;13(5): 21-7. (In Russ.)]][2. Cicinelli E, De Ziegler D, Nicoletti R, et al. Chronic endometritis: correlation among hysteroscopic, histologic, and bacteriologic findings in a prospective trial with 2190 consecutive office hysteroscopies. Fertil Steril. 2008;89:677-84. doi: 10.1016/j.fertnstert.2007.03.074.][3. Park HJ, Kim YS, Yoon TK, Lee WS. Chronic endometritis and infertility. Clin Exp Reprod Med. 2016;43(4):185-92. doi: 10.5653/cerm.2016.43.4.185.][4. Bulmer JN, Williams PJ, Lash GE. Immune cells in the placental bed. Int J Dev Biol. 2010;54:281-94. doi: 10.1387/ijdb.082763jb.][5. Tortorella C, Piazzolla G, Matteo M, et al. Interleukin-6, interleukin-1β, and tumor necrosis factor α in menstrual effluents as biomarkers of chronic endometritis. Fertil Steril. 2014;101:242-7. doi: 10.1016/ j.fertnstert.2013.09.041.][6. McQueen DB, Bernardi LA, Stephenson MD. Chronic endometritis in women with recurrent early pregnancy loss and/or fetal demise. Fertil Steril. 2014;101:1026-30. doi: 10.1016/j.fertnstert.2013.12.031.][7. Cicinelli E, Matteo M, Tinelli R, et al. Prevalence of chronic endometritis in repeated unexplained implantation failure and the IVF success rate after antibiotic therapy. Hum Reprod. 2015;30:323-30. doi: 10.1093/humrep/deu292.][8. Lee D, Jo JD, Kim SK, et al. The efficacy of intrauterine instillation of granulocyte colony-stimulating factor in infertile women with a thin endometrium: A pilot study. Clin Exp Reprod Med. 2016;43(4):240-6. doi: 10.5653/cerm.2016.43.4.240.][9. Kunicki M, Łukaszuk K, Liss J, et al. Granulocyte colony stimulating factor treatment of resistant thin endometrium in women with frozen-thawed blastocyst transfer. Syst Biol Reprod Med. 2017;63(1):49-57. doi: 10.1080/19396368.2016.1251505.][10. Lebovitz O, Orvieto R. Treating patients with “thin” endometrium – an ongoing challenge. Gynecol Endocrinol. 2014;30(6):409-14. doi: 10.3109/09513590.2014.906571.]